Dr.Reddy's Laboratories,Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$25.7M
Doctors Paid
452
Transactions
4,974
2024 Total
$792,896
Payment Breakdown by Category
Research$23.6M (92.0%)
Consulting$620,047 (2.4%)
Travel$38,224 (0.1%)
Food & Beverage$4,232 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $23.6M | 4,103 | 92.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.4M | 73 | 5.4% |
| Consulting Fee | $620,047 | 665 | 2.4% |
| Travel and Lodging | $38,224 | 45 | 0.1% |
| Food and Beverage | $4,232 | 86 | 0.0% |
| Education | $3,000 | 1 | 0.0% |
| Charitable Contribution | $150.00 | 1 | 0.0% |
Payments by Type
Research
$23.6M
4,103 transactions
General
$2.1M
871 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Tolerability, and Safety Study of DFN-15 in Episodic Migraine With or Without Aura Oral Celecoxib | $4.7M | 28 | 689 |
| Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis | $3.4M | 4 | 840 |
| A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) | $2.1M | 1 | 605 |
| DFD-03-CD-005 A Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks | $1.6M | 0 | 197 |
| DFD-03-CD-006 A Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks | $1.5M | 1 | 192 |
| DFD03-CD-007 | $1.4M | 0 | 23 |
| Dr. Reddy 1007754 | $956,927 | 1 | 167 |
| DFD-07-CD-002 A Multi-Center, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study toEvaluate the Dose-Response Relationship of the Efficacy and Safety of Two Concentrations ofDFD-07 celecoxib Cream, in Subjects with Actinic Keratosis AK of the Face andor ScalpOver a 12-week Treatment Period | $953,894 | 3 | 204 |
| Dr. Reddy 1007753 | $781,685 | 2 | 203 |
| A Phase 3 randomized, Double-Blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis to Biosimilar Rituximab (DRL_RI) or Continued Treatment With Rituxan or MabThera | $765,718 | 0 | 320 |
| DFN-15-CD-010Dental Pain Study | $678,686 | 0 | 6 |
| DFD-03-CD-008 A Randomized, Double-Blind, Vehicle and Active-Controlled Study to Assess the Safety and Local Tolerability of DFD-03 tazarotene Lotion, 0.1 compared to Tazorac tazarotene Cream, 0.1 in the Topical Treatment of Acne Vulgaris for 12 Weeks | $492,289 | 0 | 68 |
| DFN-11-CD-004A Multicenter, Randomized, Double-Blind, Palcebo-Controlled Efficacy, Tolerability and Safety Study of DFN-11 Sumitriptan 3mg in Episodic Migraine with or without Aura | $468,050 | 1 | 75 |
| A Double-blind, Parallel-group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera in Subjects With Previously Untreated (CD)20-Positive LTB Follicular Lymphoma | $437,714 | 3 | 202 |
| Amphetamine 30 mg ER | $405,206 | 0 | 14 |
| DFD-03-CD-011 A Randomized, Controlled Study to Evaluate the Sensitizing Potential of DFD-03 Lotion in Healthy Subjects Using a Repeat Insult Patch Test Design | $372,685 | 0 | 8 |
| DFD-03-CD-010 A 6-Week, Randomized Study to Evaluate the Potential of DFD-03 Lotion to Induce a Photoallergic Skin Reaction in Healthy Volunteers, Using a Controlled Photopatch Test Design | $301,377 | 0 | 6 |
| National Pregnancy Registry for Psychiatric Medications | $252,458 | 0 | 4 |
| An Open-Label, Three-Way, Randomized, Single Dose Crossover Study Comparing Bioavailability of DFN-15 Celecoxib Oral Solution 25 mgmL 120 mg of Dr. Reddys Laboratories Limited, India Under Fasting Conditions Versus CELEBREX Celecoxib 400 mg Capsules of G.D. SEARLE LLC Under Fed Conditions and to Determine Food-Effect of DFN-15 in Healthy Adult Subjects | $217,989 | 0 | 3 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of DFN-02 Sumatriptan Nasal Spray 10 mg in Episodic Migraine With or Without Aura | $212,579 | 2 | 41 |
| A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) | $206,844 | 0 | 75 |
| Pivotal PK and Adhesion Study of Buprenorphine TDS Patch 20 mcghr | $203,750 | 0 | 1 |
| Dr. Reddy Allodynia | $203,129 | 0 | 1 |
| DFD-03-CD-009 A 4-Day, Randomized, Vehicle-Controlled, Patch Test Study to Evaluate the Phototoxic Potential of DFD-03 tazarotene, 0.1 Lotion | $182,326 | 0 | 5 |
| Can Celecoxib reverse inflamatory responses in the mininges | $176,170 | 0 | 2 |
| IrritationSensitization Outpatient Study of Buprenorphine TDS Placebo Patch | $144,250 | 0 | 1 |
| The North American AED Pregnancy Registry | $133,000 | 0 | 2 |
| 11840605 A Study to Evaluate the Relative Bioavailability of a Test Rivastigmine Transdermal System,9.5 mg24 hours Dr. Reddys Laboratories Ltd. Compared to EXELON PATCHrivastigmine transdermal system, 9.5 mg24 hours Novartis Pharmaceuticals Corporation inHealthy Adult Subjects | $104,750 | 0 | 1 |
| CA20897 | $97,437 | 0 | 4 |
| A Double-blind, Parallel-group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar DRLRI With MabThera in Subjects With Previously Untreated CD20-Positive LTB Follicular Lymphoma | $66,793 | 4 | 60 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Shahram Jacobs, M.d, M.D | Internal Medicine | Encino, CA | $267,654 | $0 |
| Unknown Provider | — | — | $177,629 | $0 |
| Dr. David Kudrow, Md, MD | Neurology | Santa Moncia, CA | $112,924 | $0 |
| Dr. Raymond Tidman, Md, MD | Family Medicine | Blue Ridge, GA | $88,987 | $0 |
| Dr. Tory Sullivan, M.d, M.D | Obesity Medicine | North Miami Beach, FL | $75,740 | $0 |
| Dr. Max Rosen, Md Mph, MD MPH | Diagnostic Radiology | Worcester, MA | $66,965 | $0 |
| Dr. Adly Thebaud, Md, MD | Psychiatry | Orange City, FL | $57,066 | $0 |
| Dr. Wb Younger, Md, MD | Hematology & Oncology | Boston, MA | $48,350 | $0 |
| Leon Kircik, Md, MD | Dermatology | Lousiville, KY | $45,500 | $0 |
| Arthur Burnett, M.d, M.D | Urology | Baltimore, MD | $43,650 | $0 |
| Dr. Gary Heller, D.o, D.O | Dermatology | Pinellas Park, FL | $37,030 | $0 |
| Stephen Miller, M.d. P.a, M.D. P.A | Dermatology | San Antonio, TX | $36,995 | $0 |
| Dr. Alan Rapoport, M.d, M.D | Neurology | Los Angeles, CA | $36,425 | $0 |
| Bruce Freundlich | Rheumatology | Villanova, PA | $34,000 | $0 |
| Dr. Kent Allenby, M.d, M.D | Internal Medicine | Princeton, NJ | $28,720 | $0 |
| Edwin Pascal Alyea, M.d, M.D | Hematology & Oncology | Boston, MA | $25,750 | $0 |
| Tyler Curiel, M.d, M.D | Infectious Disease | Lebanon, NH | $25,000 | $0 |
| Pavel Klein, Md, MD | Neurology | Bethesda, MD | $24,367 | $0 |
| Guillermo Garcia-Manero, M.d, M.D | Medical Oncology | Houston, TX | $24,350 | $0 |
| Unknown Provider | — | — | $21,192 | $0 |
| Shaji Kumar, M.d, M.D | Hematology & Oncology | Rochester, MN | $17,196 | $0 |
| Robert Giugliano, Md, MD | Cardiovascular Disease | Boston, MA | $17,000 | $0 |
| Dr. Bruce Cheson, Md, MD | Hematology & Oncology | Bethesda, MD | $15,645 | $0 |
| Marc Sabatine, Md, MD | Cardiovascular Disease | Boston, MA | $15,000 | $0 |
| Dr. Herman Weiss, M.d, M.D | Obstetrics & Gynecology | Massapequa, NY | $13,130 | $0 |
Ad
Top Products
- Buprenorphine and Naloxone $1.2M
- LURASIDONE HYDROCHLORIDE $252,458
Associated Products (6)
- Buprenorphine and Naloxone $1.3M
- LURASIDONE HYDROCHLORIDE $252,458
- Lamotrigine $133,000
- Levetiracetam $123,500
- Nerivio $37,145
- Zenatane $21,860
Payment Categories
- Food & Beverage $4,232
- Consulting $620,047
- Travel & Lodging $38,224
- Research $23.6M
About Dr.Reddy's Laboratories,Inc.
Dr.Reddy's Laboratories,Inc. has made $25.7M in payments to 452 healthcare providers, recorded across 4,974 transactions in the CMS Open Payments database. In 2024, the company paid $792,896. The top product by payment volume is Buprenorphine and Naloxone ($1.2M).
Payments were distributed across 69 medical specialties. The top specialty by payment amount is Internal Medicine ($364,772 to 33 doctors).
Payment categories include: Food & Beverage ($4,232), Consulting ($620,047), Research ($23.6M), Travel & Lodging ($38,224).
Dr.Reddy's Laboratories,Inc. is associated with 6 products in the CMS Open Payments database, including Buprenorphine and Naloxone, LURASIDONE HYDROCHLORIDE, and Lamotrigine.